Greenlight Biosciences Holdings PBC

Company Profile

Greenlight Biosciences Holdings PBC had its IPO on 2022-02-03 under the ticker symbol GRNA.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Greenlight Biosciences Holdings PBC has a staff strength of 0 employees.

Stock update

Shares of Greenlight Biosciences Holdings PBC opened at $0.3 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.3 - $0.3, and closed at $0.3.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Greenlight Biosciences Holdings PBC have increased by +0.84%.

Greenlight Biosciences Holdings PBC's Key Ratios

Greenlight Biosciences Holdings PBC has a market cap of $45.43 million, indicating a price to book ratio of 2.1364 and a price to sales ratio of 41.4116.

In the last 12-months Greenlight Biosciences Holdings PBC’s revenue was $10.34 million with a gross profit of $-87219000 and an EBITDA of $-146159008. The EBITDA ratio measures Greenlight Biosciences Holdings PBC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Greenlight Biosciences Holdings PBC’s operating margin was -1493.5% while its return on assets stood at -81.78% with a return of equity of -366.87%.

In Q1, Greenlight Biosciences Holdings PBC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1386.4%.

Greenlight Biosciences Holdings PBC’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Greenlight Biosciences Holdings PBC’s profitability.

Greenlight Biosciences Holdings PBC stock is trading at a EV to sales ratio of 32.492 and a EV to EBITDA ratio of -1.8414. Its price to sales ratio in the trailing 12-months stood at 41.4116.

Greenlight Biosciences Holdings PBC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$113.69 million

Total Liabilities

$31.19 million

Operating Cash Flow

$-1608000.00

Capital Expenditure

$1.61 million

Dividend Payout Ratio

0%

Greenlight Biosciences Holdings PBC ended 2024 with $113.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $113.69 million while shareholder equity stood at $21.94 million.

Greenlight Biosciences Holdings PBC ended 2024 with $0 in deferred long-term liabilities, $31.19 million in other current liabilities, 15000.00 in common stock, $-449107000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $32.35 million and cash and short-term investments were $32.35 million. The company’s total short-term debt was $17,865,000 while long-term debt stood at $10.86 million.

Greenlight Biosciences Holdings PBC’s total current assets stands at $37.70 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.07 million and inventory worth $0.

In 2024, Greenlight Biosciences Holdings PBC's operating cash flow was $-1608000.00 while its capital expenditure stood at $1.61 million.

Comparatively, Greenlight Biosciences Holdings PBC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.3

52-Week High

$2.51

52-Week Low

$0.177

Analyst Target Price

$0.45

Greenlight Biosciences Holdings PBC stock is currently trading at $0.3 per share. It touched a 52-week high of $2.51 and a 52-week low of $2.51. Analysts tracking the stock have a 12-month average target price of $0.45.

Its 50-day moving average was $0.28 and 200-day moving average was $0.82 The short ratio stood at 0.78 indicating a short percent outstanding of 0%.

Around 4290.6% of the company’s stock are held by insiders while 2685.1% are held by institutions.